Metra plans to slash costs while seeking new partnerships
This article was originally published in Clinica
Metra Biosystems has announced a plan to significantly reduce its operating expenses next year. The move follows an already reduced cash burn in fiscal 1998 and the company is optimistic that its partnerships with major companies will prompt increased revenue next year. At the end of the last financial year the company had +ACQ-27 million and last year turned in net losses of +ACQ-12 million.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.